AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 29, 2024
(Dave & Les Jacobs/DigitalVision/Getty Images) We know that too much sitting is bad for us, but a new study adds an important detail: if you spend more than 10-and-a-half hours a day sitting or lying down, regular exercise might not be enough to prevent an increased risk of serious heart issues.
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
DECEMBER 29, 2024
FENTORA (fentanyl citrate) Cephalon Patent: 8,119,158 Expiration: Dec 30, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 29, 2024
The Punjab Drug Manufacturers Association (PDMA) has requested Prime Minister Narendra Modi to give more time to the micro and small units under Rs. 10 crore, who have not availed tax holiday benefits, for at least three years to comply with the Revised Schedule M standards.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
196 
Let's personalize your content